ZHEJIANG STARRY PHARMACEUTICAL CO.,LTDZHEJIANG STARRY PHARMACEUTICAL CO.,LTDZHEJIANG STARRY PHARMACEUTICAL CO.,LTD

ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD

No trades
See on Supercharts

603520 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Zhejiang Starry Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of active ingredient and intermediate X-CT non-ionic contrast agent and fluoroquinolones series. Its products include fluorine quinoline derivatives, carbapenem, iohexol, ioversol, iopamidol, iopromide, iodixanol, levofloxacin, levofloxacin hydrochloride, levofloxacin acid ester, levofloxacin acid, pazufloxacin, pazufloxacin mesylate, meropenem, faropenem sodium, iomeprol, and gadobenate dimeglumine. The company was founded on September 15, 1997 and is headquartered in Taizhou, China.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

603520 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company